DBV Technologies Announces Primary Endpoint Met in VIPES, Viaskin Peanut's Phase IIb Clinical Trial in Peanut Allergy

  • Largest clinical trial in peanut allergy desensitization ever completed, VIPES meets primary endpoint with Viaskin® Peanut at the 250 µg dose
  • Safety profile confirmed and excellent patient compliance demonstrated

BAGNEUX, France, September 22, 2014 - DBV Technologies, (Euronext: DBV - ISIN: FR0010417345), today announced topline results for its VIPES (Viaskin Peanut's Efficacy and Safety) phase IIb clinical trial of Viaskin Peanut in peanut allergic patients. The trial met its primary endpoint at the highest explored dose (Viaskin Peanut 250 µg), achieving statistical significance (p=0.0108) in desensitizing a higher proportion of patients versus placebo after 12 months of Epicutaneous Immunotherapy (EPIT). Patients treated with Viaskin Peanut 250 µg also showed statistically significant changes in measured serological markers while placebo patients did not exhibit material differences. The safety profile was confirmed across all active arms with no serious treatment-related adverse events reported, and patient compliance with daily Viaskin Peanut application was above 97%. The trial drop-out rate was 6.4%, below the 15% rate initially anticipated. The VIPES trial is the largest clinical trial in peanut allergy desensitization ever completed, and full results of efficacy and safety will presented at future scientific meetings.

To download the full version of the Press Release in English language, please click on the following link: